期刊文献+

药品零售企业网售处方药风险及对策研究 被引量:1

Study on the risk and countermeasure of prescription drugs sold online by drug retail enterprises
下载PDF
导出
摘要 目的分析药品零售企业网售处方药风险,为网售处方药的风险防控提供对策建议。方法采用层次分析法构建药品零售企业网售处方药风险层次结构模型,再进行风险判断矩阵的归一化权重计算和一致性检验;采用德尔菲专家调查法对123对评价指标进行多轮风险研判,开展模糊定量研究。结果药品零售企业网售处方药风险中的处方调剂及审核风险(6.48%)、先药后方风险(5.48%)、合理用药指导风险(4.99%)、非正常用途购买药品风险(4.97%)、“首诊、非慢性病、非常见病”风险(4.43%)、退货药品质量安全风险(4.34%)、监管技术应用风险(4.06%)为高风险点;药品零售企业(连锁)网售处方药的总体风险为38.67%,药品零售企业(单体)网售处方药的总体风险为61.33%,两者之间相差22.66%。结论药品零售企业网售处方药高风险指标有7个,其中处方调剂及审核风险、先药后方风险、合理用药指导风险为排名前3位的高风险点;药品零售企业(单体)网售处方药的风险要高于药品零售企业(连锁)。建议监管部门重点关注并规范药品零售企业(单体)的网售处方药行为,鼓励药品零售企业(连锁)建立系统的处方药网售流程;对于网售处方药的高风险点,建议监管部门和药品零售企业重点关注并采取有效风险防控措施,以保障老百姓网购处方药的安全用药权益。 OBJECTIVE To analyze the risks of prescription drugs sold online by drug retail enterprises,and to provide countermeasures and suggestions for risk prevention and control of prescription drugs sold online.METHODS The risk hierarchy structure model of prescription drugs sold online by drug retail enterprises was constructed by using analytic hierarchy process.Multiple rounds of risk research and judgment were carried out on 123 pairs of evaluation indicators by using Delphi expert survey method.The normalized weight calculation and consistency test of risk judgment matrix were carried out to perform fuzzy quantitative research.RESULTS The risk of prescription dispensing and review(6.48%),the risk of drug first and prescription later(5.48%),the risk of rational drug use guidance(4.99%),the risk of buying drugs by abnormal channel(4.97%),the risk of“first diagnosis,non-chronic disease and non-common disease”(4.43%),and the quality and safety risk of returned drugs(4.34%)and the application risk of regulatory technology(4.06%)were high risks;the overall risk of drug retail enterprises(chain)selling prescription drugs online was 38.67%,and the overall risk of drug retail enterprises(individual)selling prescription drugs online was 61.33%,with a difference of 22.66%between them.CONCLUSIONS There were 7 high-risk indicators for prescription drugs sold online by drug retail enterprises.Among them,the risk of prescription dispensing and review,the risk of drug first and prescription later,and the risk of rational drug use guidance are the top three high-risk points.The risk of prescription drugs sold online by drug retail enterprises(individual)is higher than that of drug retail enterprises(chain).It is recommended that regulatory authorities focus on and regulate the prescription drugs sold online by drug retail enterprises(individual),and encourage drug retail enterprises(chain)to establish a systematic online sales process for prescription drugs;for high-risk points of prescription drugs sold online,it is recommended that regulatory authorities and drug retail enterprises focus on it and take effective risk prevention and control measures to ensure the safe use of prescription drugs by the general public.
作者 施能进 丁静 王刚 胡卫江 王蓓 虞敏 SHI Nengjin;DING Jing;WANG Gang;HU Weijiang;WANG Bei;YU Min(School of Pharmaceutical Business,Zhejiang Pharmaceutical Vocational University,Zhejiang Ningbo 315500,China;Dept.of Pharmacy,Hangzhou First People’s Hospital Affiliated to Zhejiang University School of Medicine,Hangzhou 310006,China;Hangzhou Drug Inspection Center,Hangzhou 310004,China;SPN Ningbo Pharmaceutical Co.,Ltd.,Zhejiang Ningbo 315000,China;East China Pharmaceutical Supply Chain Management(Hangzhou)Co.,Ltd.,Hangzhou 310018,China)
出处 《中国药房》 CAS 北大核心 2023年第9期1031-1037,共7页 China Pharmacy
基金 浙江省哲学社会科学规划课题(No.20NDJC221YB)。
关键词 药品零售企业 网售处方药 风险 监管 单体 连锁 drug retail enterprises prescription drugs sold online risk regulation monomers chain
  • 相关文献

参考文献8

二级参考文献37

  • 1潘桂玲.本院门诊药房退药分析与解决办法[J].医学信息,2017,30(6):10-11. 被引量:2
  • 2钱颂迪.运筹学[M].北京:清华大学出版社,2000,3..
  • 3卢岚.安全工程[M].天津:天津大学出版社,2002..
  • 42016—2021年中国医药行业市场前瞻与投资战略规划分析报告[R].深圳:前瞻产业研究院,2016.
  • 5来春潮.网售处方药监管要跨过哪些槛[N].医药经济报,2015-01-26(2).
  • 6Scott MB. Effective management of prescription drug benefit is crucial to health care cost containment [ J ]. Employee Benefit Plan Rev, 2001(5) : 21-22.
  • 7Grabowski H, Mullins C D. Pharmacy benefit management, cost-effectiveness analysis and drug formulary decisions [J]. Social science & medicine, 1997, 45 (4) : 535-544.
  • 8Lipton H L, Kreling D H, Collins T, et al. Pharmacy benefit management companies : dimensions of performance [ J ]. An- num review of public health, 1999(20) : 361-401.
  • 9Daugherty L, Condie A. Systems and methods for accelerated payment of pharmacy prescription claims [ P ]. USA. US 2007/0136100 A1. 2007-06-t4.
  • 10Garis Robert I, Clark Bartholomew E, Siracuse Mark V, et al. Examining the value of pharmacy benefit management companies[ J]. American Journal of Health-System Pharma- cy, 2004(61): 81-85.

共引文献499

同被引文献9

引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部